Ocular Therapeutix, Inc.

NASDAQ:OCUL

Biotechnology

Healthcare
$5.94 -1.17%

-$0.11 today

Market cap
$1.31B
Beta
0.90
P/E (TTM)
-7.3
EPS (TTM)
-$1.30
52W Low $6.23High $16.44

Volume 3.67M

Average 3.00M

OCUL Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Ocular Therapeutix, Inc.NASDAQ: OCUL

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $88.61M (cash outflow) rose 38.3% year over year, behind the +50.7% change in trailing-twelve-month net income. Sequentially, it rose 37.1% from the prior quarter. Over 3 fiscal years it compounded at +55.3% a year.

Context

  • Net income amounted to 513.2% of revenue in FY2025, up 209.5 pp from a year earlier.
  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 9 analysts of -$298.01M (+12.1%) for the fiscal year ending Dec 2026, a slowdown from the +37.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$88.61M+37.1% QoQ
Last fiscal yearDec 2025
-$265.94M+37.4% YoY
LTMMar 2026
-$290.5M+50.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+38.3%+31.5%-6.8 pp
1 year+37.4%+12.1%-25.4 pp
3-year CAGR+55.3%+3.8%-51.5 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(265.94M) USD
Year-over-year change
-37.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How OCUL compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +50.7% is the 3rd highest of 10, against a peer median of -8.3%.
  • Net income amounts to 558.2% of revenue for OCUL, versus a peer median of 818.0%.
OCUL Competitors
Net Income for OCUL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OCULOcular Therapeutix, Inc.LTM Mar 2026$290.5M USD+50.7%+55.3%558.2%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$271.6M USD+85.0%+31.4%3566.6%
KODKodiak Sciences Inc.LTM Sep 2026$246.76M USD+13.5%-11.7%—
GKOSGlaukos CorporationLTM Jun 2026$188.05M USD+102.7%+10.5%30.7%
BLCOBausch + Lomb CorporationLTM Jun 2026$167M USD-36.5%—3.1%
OCSOculis Holding AGLTM Mar 2026CHF 94.54M CHF-8.3%+34.7%18758.0%
OCGNOcugen, Inc.LTM Mar 2026$71.67M USD+24.7%-7.9%1605.2%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$60.96M USD-388.6%-1.9%18297.5%
SGPSpyGlass Pharma, Inc. Common StockFY2025$39.87M USD———
STAASTAAR Surgical CompanyLTM Apr 2026$21.03M USD-70.4%—7.2%
HROWHarrow Health, Inc.LTM Mar 2026$14.96M USD-31.0%-28.5%5.6%
Peer median (excluding OCUL) —-8.3%-1.9%818.0%

Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Depreciation & Amortization2.42M2.11M2.98M3.79M4.32M
Deferred Income Tax00000
Stock-Based Compensation14.98M16.96M17.83M33.11M43.18M
Change in Working Capital(2.9M)1.35M(7.41M)(10.23M)7.71M
Accounts Receivables(8.88M)(190K)(4.85M)(6.21M)1.74M
Inventory(49K)(724K)(331K)(735K)(524K)
Accounts Payables1.8M(621K)583K(318K)(887K)
Other Working Capital4.24M2.88M(2.81M)(2.97M)7.38M
Other Non-Cash Items(73.49M)(8.99M)(2.9M)32.16M5.84M
Operating Cash Flow(65.55M)(59.6M)(70.23M)(134.68M)(204.88M)
Capital Expenditures(1.19M)(3.72M)(6.09M)(1.29M)(12.01M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0000130K
Investing Cash Flow(1.19M)(3.72M)(6.09M)(1.29M)(11.88M)
Debt Repayment(445K)056.35M316.35M0
Common Stock Issued985K940K118.11M316.35M561.72M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.31M514K(4.63M)(300.6M)0
Financing Cash Flow2.85M1.45M169.83M332.11M561.72M
Effect of Forex Changes00000
Net Change in Cash(63.89M)(61.86M)93.51M196.15M344.96M
Free Cash Flow(66.74M)(63.32M)(76.32M)(135.97M)(216.89M)

Ocular Therapeutix, Inc.

NASDAQ:OCUL

Intrinsic Alpha fair value

Locked

Current Price

$5.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.